Weaver Capital Management LLC Boosts Position in Johnson & Johnson $JNJ

Weaver Capital Management LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 56.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 18,084 shares of the company’s stock after buying an additional 6,535 shares during the period. Weaver Capital Management LLC’s holdings in Johnson & Johnson were worth $3,353,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in JNJ. Brighton Jones LLC grew its stake in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares in the last quarter. United Bank boosted its holdings in Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares during the period. Bosun Asset Management LLC grew its position in Johnson & Johnson by 12.2% in the first quarter. Bosun Asset Management LLC now owns 2,694 shares of the company’s stock valued at $447,000 after acquiring an additional 293 shares in the last quarter. Curi RMB Capital LLC raised its stake in shares of Johnson & Johnson by 9.4% during the first quarter. Curi RMB Capital LLC now owns 92,945 shares of the company’s stock valued at $15,414,000 after purchasing an additional 8,011 shares during the period. Finally, Clark Capital Management Group Inc. lifted its position in shares of Johnson & Johnson by 23.4% during the first quarter. Clark Capital Management Group Inc. now owns 504,799 shares of the company’s stock worth $83,716,000 after purchasing an additional 95,755 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $207.07 on Friday. The stock has a market capitalization of $498.89 billion, a price-to-earnings ratio of 19.99, a PEG ratio of 2.24 and a beta of 0.36. Johnson & Johnson has a one year low of $140.68 and a one year high of $215.18. The company’s 50-day simple moving average is $200.83 and its 200-day simple moving average is $182.27. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Royal Bank Of Canada set a $240.00 target price on Johnson & Johnson in a research note on Wednesday, December 17th. HSBC reiterated a “buy” rating and issued a $240.00 price target on shares of Johnson & Johnson in a research note on Wednesday, December 10th. Loop Capital set a $190.00 price target on Johnson & Johnson in a report on Wednesday, October 22nd. Finally, Argus set a $210.00 price objective on Johnson & Johnson in a report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $211.25.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.